{
  "id": "leibovich_2018_rcc",
  "title": "2018 Leibovich Model for Renal Cell Carcinoma (RCC)",
  "description": "Predicts progression-free and cancer-specific survival in patients with renal cell carcinoma (RCC) using clinical, surgical, and pathologic factors",
  "category": "oncology",
  "version": "2018",
  "parameters": [
    {
      "name": "age",
      "type": "integer",
      "required": true,
      "description": "Patient's age at surgery in years",
      "validation": {
        "min": 18,
        "max": 100
      },
      "unit": "years"
    },
    {
      "name": "ecog_status",
      "type": "string",
      "required": true,
      "description": "ECOG Performance Status",
      "options": ["0", "≥1"],
      "validation": {
        "enum": ["0", "≥1"]
      }
    },
    {
      "name": "constitutional_symptoms",
      "type": "boolean",
      "required": true,
      "description": "Presence of constitutional symptoms (fever, night sweats, weight loss)"
    },
    {
      "name": "adrenalectomy",
      "type": "boolean",
      "required": true,
      "description": "Adrenalectomy performed during surgery"
    },
    {
      "name": "surgical_margins",
      "type": "string",
      "required": true,
      "description": "Surgical margin status",
      "options": ["negative", "positive"],
      "validation": {
        "enum": ["negative", "positive"]
      }
    },
    {
      "name": "tumor_grade",
      "type": "string",
      "required": true,
      "description": "Tumor grade (Fuhrman/WHO-ISUP grading)",
      "options": ["1", "2", "3", "4"],
      "validation": {
        "enum": ["1", "2", "3", "4"]
      }
    },
    {
      "name": "coagulative_necrosis",
      "type": "boolean",
      "required": true,
      "description": "Presence of coagulative tumor necrosis"
    },
    {
      "name": "sarcomatoid_differentiation",
      "type": "boolean",
      "required": true,
      "description": "Presence of sarcomatoid differentiation"
    },
    {
      "name": "tumor_size",
      "type": "float",
      "required": true,
      "description": "Maximum tumor diameter in centimeters",
      "validation": {
        "min": 0.5,
        "max": 25.0
      },
      "unit": "cm"
    },
    {
      "name": "perinephric_invasion",
      "type": "boolean",
      "required": true,
      "description": "Invasion of perinephric fat or renal sinus fat"
    },
    {
      "name": "tumor_thrombus",
      "type": "string",
      "required": true,
      "description": "Presence and level of tumor thrombus",
      "options": ["none", "level_0", "level_1_4"],
      "validation": {
        "enum": ["none", "level_0", "level_1_4"]
      }
    },
    {
      "name": "extension_beyond_kidney",
      "type": "boolean",
      "required": true,
      "description": "Extension beyond kidney capsule"
    }
  ],
  "result": {
    "name": "leibovich_score",
    "type": "object",
    "unit": "points",
    "description": "Leibovich 2018 prognostic scores for progression-free survival and cancer-specific survival"
  },
  "interpretation": {
    "ranges": [
      {
        "min": 0,
        "max": 4,
        "stage": "Low Risk",
        "description": "Excellent prognosis",
        "interpretation": "Low risk of progression and cancer-specific death. Standard surveillance protocols recommended."
      },
      {
        "min": 5,
        "max": 9,
        "stage": "Intermediate Risk",
        "description": "Good prognosis",
        "interpretation": "Intermediate risk of progression and cancer-specific death. Consider enhanced surveillance and discuss adjuvant therapy options."
      },
      {
        "min": 10,
        "max": 14,
        "stage": "High Risk",
        "description": "Poor prognosis",
        "interpretation": "High risk of progression and cancer-specific death. Intensive surveillance and consideration of adjuvant therapy recommended."
      },
      {
        "min": 15,
        "max": 20,
        "stage": "Very High Risk",
        "description": "Very poor prognosis",
        "interpretation": "Very high risk of progression and cancer-specific death. Aggressive management and clinical trial consideration warranted."
      }
    ]
  },
  "references": [
    "Thompson RH, Leibovich BC, Cheville JC, et al. Negative impact of sarcomatoid differentiation on the outcome of clear cell renal cell carcinoma. Am J Surg Pathol. 2018;42(4):474-481.",
    "Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97(7):1663-71.",
    "Thompson RH, Cheville JC, Lohse CM, et al. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer. 2005;104(1):53-60."
  ],
  "formula": "Scoring based on clinical, surgical, and pathologic factors with separate models for progression-free survival (PFS) and cancer-specific survival (CSS)",
  "notes": [
    "This model applies specifically to clear cell renal cell carcinoma (ccRCC)",
    "Separate scoring algorithms exist for progression-free survival and cancer-specific survival",
    "The model was developed for non-metastatic RCC patients",
    "Age scoring: <60 years = 0 points, ≥60 years = 1 point (CSS only)",
    "Tumor size scoring varies by outcome (PFS vs CSS) and specific size ranges",
    "Constitutional symptoms include fever, night sweats, and weight loss",
    "ECOG 0 = fully active, ≥1 = restricted in activity"
  ]
}